NON-HODGKIN'S LYMPHOMA
Clinical trials for NON-HODGKIN'S LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new NON-HODGKIN'S LYMPHOMA trials appear
Sign up with your email to follow new studies for NON-HODGKIN'S LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested the safety of the drug nivolumab, alone or combined with other drugs like daratumumab, in 320 people with blood cancers (lymphoma or multiple myeloma) that had returned or stopped responding to treatment. The main goal was to track serious side effects. This is …
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Can we skip the booster? new study tests simpler recovery after stem cell transplant
Disease control CompletedThis study looked at 77 people with multiple myeloma or non-Hodgkin lymphoma who had a stem cell transplant. Half got a drug called tbo-filgrastim (a growth factor) after transplant, and half did not. The goal was to see if skipping the drug still allowed patients to leave the ho…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Could a drug make stem cell transplants safer and more effective?
Disease control CompletedThis study tested a drug called palifermin in 34 adults with blood cancers who received stem cell transplants from unrelated donors. The goal was to see if palifermin could reduce severe chronic graft-versus-host disease (GVHD), a serious complication where donor cells attack the…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC